Movement Disorder News and Research

Latest Movement Disorder News and Research

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Ampicillin activates torsinA, improves cell function to reduce movement disorders

DSPA's lurasidone NDA accepted for FDA review

DSPA's lurasidone NDA accepted for FDA review

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

NAF to hold third annual Ataxia Investigators Meeting in Rosemont

NAF to hold third annual Ataxia Investigators Meeting in Rosemont

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Allergan celebrates 20th anniversary of BOTOX in Canada

Allergan celebrates 20th anniversary of BOTOX in Canada

Focal dystonia precipitated by odor exposure: First case reported

Focal dystonia precipitated by odor exposure: First case reported

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Medtronic third-quarter revenues up by 10%

Medtronic third-quarter revenues up by 10%

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

New foundational research may advance pharmacological therapies for neurological disorders

New foundational research may advance pharmacological therapies for neurological disorders

Journal highlights toxic nature of herbal medicines

Journal highlights toxic nature of herbal medicines

New revolutionary treatment for patients suffering from movement disorders

New revolutionary treatment for patients suffering from movement disorders

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

Simulation training may help improve driving skills of Parkinson's disease patients

Simulation training may help improve driving skills of Parkinson's disease patients

CAMH signs licensing agreement to develop and market genetic test for degenerative muscle disorder

CAMH signs licensing agreement to develop and market genetic test for degenerative muscle disorder

Large research gap exists in effectiveness, mechanism and safety of drugs in children

Large research gap exists in effectiveness, mechanism and safety of drugs in children

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.